Hydrolysis of the intense sweetener neohesperidin dihydrochalcone in water–organic solvent mixtures

Montijano, Helena; Borrego, Francisco Javier Escobar

doi:10.1046/j.1365-2621.1999.00259.x

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other authors (Montijano and Borrego, 1999) tested the stability of neohesperidine dihydrochalcone in two water‐solvent mixture model systems (water‐ethanol and water‐glycerol) at a concentration of 300 mg/L under accelerated conditions (70, 80, 90°C) and buffered at pH 3. Samples were taken at different time intervals, until the concentration of neohesperidine dihydrochalcone was 75% or less.…”

Section: Assessmentmentioning

confidence: 99%

Re‐evaluation of neohesperidine dihydrochalcone (E 959) as a food additive

Younes¹,

Aquilina²,

Castle³

et al. 2022

EFS2

View full text Add to dashboard Cite

The present opinion deals with the re‐evaluation of neohesperidine dihydrochalcone (E 959) when used as a food additive. It is obtained by catalytic hydrogenation of a flavanone – neohesperidine – which is naturally occurring and thus isolated by alcohol extraction in bitter oranges (Citrus aurantium). Based on in vivo data in rat, neohesperidine dihydrochalcone is likely to be absorbed, also in humans, and to become systemically available. It does not raise a concern regarding genotoxicity. The toxicity data set consisted of studies on subchronic and prenatal developmental toxicity. No human studies were available. The data set was considered sufficient to derive a new acceptable daily intake (ADI). Based on the weight of evidence (WoE) analysis, the Panel considered unlikely that neohesperidine dihydrochalcone would lead to adverse effects on health in animals in the dose ranges tested. The Panel also considered that a carcinogenicity study was not warranted and that the lack of human data did not affect the overall confidence in the body of evidence. The Panel derived an ADI of 20 mg/kg bodyweight (bw) per day based on a no observed adverse effect level (NOAEL) of 4,000 mg/kg bw per day from a 13‐week study in rat, applying the standard default factors of 100 for inter‐ and intraspecies differences and of 2 for extrapolation from subchronic to chronic exposure. For the refined brand‐loyal exposure assessment scenario, considered to be the most appropriate for the risk assessment, the exposure estimates at the mean ranged from < 0.01 to 0.09 mg/kg bw per day and at the 95th percentile (P95) from 0.01 to 0.24 mg/kg bw per day. Considering the derived ADI of 20 mg/kg bw per day, the exposure estimates were below the reference value in all age groups. Therefore, the Panel concluded that dietary exposure to the food additive neohesperidine dihydrochalcone (E 959) at the reported uses and use levels would not raise a safety concern.

show abstract

Section: Assessmentmentioning

confidence: 99%